AbbVie, Teva Sued by FTC Over Delay in Generic AndroGel
This article is for subscribers only.
AbbVie Inc. and Teva Pharmaceutical Industries Ltd. were sued by U.S. regulators for allegedly colluding to delay introduction of a generic version of low-testosterone drug AndroGel.
An agreement between AbbVie, the maker of AndroGel, and Teva is anticompetitive and blocked consumers’ access to a lower-cost alternative to the testosterone-replacement drug, the Federal Trade Commission said in a statement today.